These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Pharmacokinetic Analysis of Mycophenolate Mofetil and Enteric-Coated Mycophenolate Sodium in Calcineurin Inhibitor-Free Renal Transplant Recipients. Graff J; Scheuermann EH; Brandhorst G; Oellerich M; Gossmann J Ther Drug Monit; 2016 Jun; 38(3):388-92. PubMed ID: 26829599 [TBL] [Abstract][Full Text] [Related]
5. Mycophenolate, clinical pharmacokinetics, formulations, and methods for assessing drug exposure. Tett SE; Saint-Marcoux F; Staatz CE; Brunet M; Vinks AA; Miura M; Marquet P; Kuypers DR; van Gelder T; Cattaneo D Transplant Rev (Orlando); 2011 Apr; 25(2):47-57. PubMed ID: 21190834 [TBL] [Abstract][Full Text] [Related]
6. Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in maintenance renal transplant recipients receiving tacrolimus: clinical, pharmacokinetic, and pharmacodynamic outcomes. Budde K; Glander P; Krämer BK; Fischer W; Hoffmann U; Bauer S; Grohmann J; Neumayer HH; Arns W Transplantation; 2007 Feb; 83(4):417-24. PubMed ID: 17318074 [TBL] [Abstract][Full Text] [Related]
7. Evalutation of mycophenolic acid systemic exposure by limited sampling strategy in kidney transplant recipients receiving enteric-coated mycophenolate sodium (EC-MPS) and cyclosporine. Capone D; Tarantino G; Kadilli I; Polichetti G; Basile V; Federico S; Sabbatini M Nephrol Dial Transplant; 2011 Sep; 26(9):3019-25. PubMed ID: 21317409 [TBL] [Abstract][Full Text] [Related]
8. No relevant pharmacokinetic interaction between pantoprazole and mycophenolate in renal transplant patients: a randomized crossover study. Rissling O; Glander P; Hambach P; Mai M; Brakemeier S; Klonower D; Halleck F; Singer E; Schrezenmeier EV; Dürr M; Neumayer HH; Budde K Br J Clin Pharmacol; 2015 Nov; 80(5):1086-96. PubMed ID: 25913040 [TBL] [Abstract][Full Text] [Related]
9. A prospective analysis of the effects of enteric-coated mycophenolate sodium and mycophenolate mofetil co-medicated with a proton pump inhibitor in kidney transplant recipients at a single institute in China. Xu L; Cai M; Shi BY; Li ZL; Li X; Jin HL Transplant Proc; 2014 Jun; 46(5):1362-5. PubMed ID: 24935300 [TBL] [Abstract][Full Text] [Related]
10. Population Pharmacokinetics and Bayesian Estimation of Mycophenolic Acid Exposure in Chinese Renal Allograft Recipients After Administration of EC-MPS. Chen B; Shao K; An HM; Shi HQ; Lu JQ; Zhai XH; Liu XX; Wang XH; Xu D; Zhou PJ J Clin Pharmacol; 2019 Apr; 59(4):578-589. PubMed ID: 30537048 [TBL] [Abstract][Full Text] [Related]
11. Therapeutic drug monitoring of mycophenolate mofetil and enteric-coated mycophenolate sodium in patients with systemic lupus erythematosus. Djabarouti S; Duffau P; Lazaro E; Chapouly C; Greib C; Viallard JF; Pellegrin JL; Saux MC; Breilh D Expert Opin Pharmacother; 2010 Apr; 11(5):689-99. PubMed ID: 20210680 [TBL] [Abstract][Full Text] [Related]
12. Randomized crossover study to assess the inter- and intrasubject variability of morning mycophenolic acid concentrations from enteric-coated mycophenolate sodium and mycophenolate mofetil in stable renal transplant recipients. Tedesco-Silva H; Felipe CR; Park SI; Pinheiro-Machado PG; Garcia R; Slade A; Schmouder R; Medina-Pestana JO Clin Transplant; 2010; 24(4):E116-23. PubMed ID: 20047618 [TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and variability of mycophenolic acid from enteric-coated mycophenolate sodium compared with mycophenolate mofetil in de novo heart transplant recipients. Hummel M; Yonan N; Ross H; Miller LW; Sechaud R; Balez S; Koelle EU; Gerosa G; Clin Transplant; 2007; 21(1):18-23. PubMed ID: 17302587 [TBL] [Abstract][Full Text] [Related]
14. Comparison of the exposure of mycophenolate mofetil and enteric-coated mycophenolate sodium in recipients of kidney-pancreas transplantation. Belliere J; Esposito L; Gandia P; Duffas JP; Sallusto F; Cardeau-Desangles I; Del Bello A; Rostaing L; Kamar N Ann Transplant; 2014 Feb; 19():76-81. PubMed ID: 24509827 [TBL] [Abstract][Full Text] [Related]
15. Lower dosing of enteric-coated mycophenolate sodium (Myfortic) can achieve target mycophenolic acid exposure rapidly in most Chinese renal transplant patients: a pilot study. Yin H; Qiu K; Hu XP; Li XB; Wang W; Liu LH; Zhang XD Int J Clin Pract Suppl; 2014 Apr; (181):31-7. PubMed ID: 24673717 [TBL] [Abstract][Full Text] [Related]
17. Influence of sex and race on mycophenolic acid pharmacokinetics in stable African American and Caucasian renal transplant recipients. Tornatore KM; Meaney CJ; Wilding GE; Chang SS; Gundroo A; Cooper LM; Gray V; Shin K; Fetterly GJ; Prey J; Clark K; Venuto RC Clin Pharmacokinet; 2015 Apr; 54(4):423-34. PubMed ID: 25511793 [TBL] [Abstract][Full Text] [Related]
18. Estimation of Mycophenolic Acid Area Under the Curve With Limited-Sampling Strategy in Chinese Renal Transplant Recipients Receiving Enteric-Coated Mycophenolate Sodium. Jia Y; Peng B; Li L; Wang J; Wang X; Qi G; Rong R; Wang L; Qiu J; Xu M; Zhu T Ther Drug Monit; 2017 Feb; 39(1):29-36. PubMed ID: 27941535 [TBL] [Abstract][Full Text] [Related]
19. Better mycophenolic acid 12-hour trough level after enteric-coated mycophenolate sodium in patients with gastrointestinal intolerance to mycophenolate mofetil. Sánchez Fructuoso A; Calvo N; Moreno MA; Giorgi M; Conesa J; Barrientos A Transplant Proc; 2007 Sep; 39(7):2194-6. PubMed ID: 17889135 [TBL] [Abstract][Full Text] [Related]
20. Evaluation of mycophenolic acid exposure using a limited sampling strategy in renal transplant recipients. Li J; Liu Y; Huang J; Fu Q; Chen E; Liu L; Zhang R; Huang M; Wang C Am J Nephrol; 2013; 37(6):534-40. PubMed ID: 23689735 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]